Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

Patent metadata

Field	Value
Publication number	US-11326211-B2
Application number	US-201615565233-A
Country	US
Kind code	B2
Filing date	Apr 12, 2016
Priority date	Apr 17, 2015
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

First claim

The invention claimed is:

1. A method of treating a patient diagnosed with a tumor which comprises:
(a) collecting a baseline blood sample from the patient prior to administering a dose of a PD-1 antagonist to the patient,
(b) administering at least one dose of a PD-1 antagonist to the patient for a treatment cycle,
(c) collecting a post-dose blood sample from the patient after the treatment cycle of the at least one dose of the PD-1 antagonist,
(d) obtaining a signature score for a gene signature biomarker in each of the baseline and post-dose blood samples, and
(e) treating the patient with a therapeutic regimen that comprises administering a PD-1 antagonist if the post-dose signature score is greater than the baseline signature score or treating the subject with a therapeutic regimen that does not include administering a PD-1 antagonist if the post-dose score is equal to or less than the baseline score;
wherein the gene signature biomarker comprises PD-L1, PD-L2, LAG3, STAT1, and CXCL10.

2. The method of claim 1 , wherein the gene signature biomarker comprises PD-L1, PD-L2, LAG3, STAT1, CXCL10, and CLEC10 a.

3. The method of claim 2 , wherein the gene signature biomarker comprises CCR5, CLEC10 a , CXCL9, CXCL10, CXCL11, GZMA, HLA-DRA, IDO1, IFNG, LAG3, PD-L1, PD-L2, PRF1, and STAT1.

4. The method of claim 3 , wherein the PD-1 antagonist is pembrolizumab in steps (b) and (e).

5. The method of claim 4 , wherein the pembrolizumab is administered to the patient on day 1 of the treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

6. The method of claim 3 , wherein the PD-1 antagonist is administered to the patient on day 1 of the treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

7. The method of claim 3 , wherein the tumor is melanoma.

8. The method of claim 2 , wherein the PD-1 antagonist is pembrolizumab in steps (b) and (e).

9. The method of claim 8 , wherein the pembrolizumab is administered to the patient on day 1 of the treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

10. The method of claim 2 , wherein the PD-1 antagonist is administered to the patient on day 1 of the treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

11. The method of claim 2 , wherein the tumor is melanoma.

12. The method of claim 1 , wherein the PD-1 antagonist is pembrolizumab in steps (b) and (e).

13. The method of claim 12 , wherein the pembrolizumab is administered to the patient on day 1 of the first treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

14. The method of claim 13 , wherein the tumor is melanoma.

15. The method of claim 12 , wherein the tumor is melanoma.

16. The method of claim 1 , wherein the PD-1 antagonist is administered to the patient on day 1 of the treatment cycle, and the post-dose blood sample is collected on the last day of the treatment cycle or on the first day of a second treatment cycle, prior to administration of a first dose of the second treatment cycle.

17. The method of claim 12 , wherein the tumor is melanoma.

18. The method of claim 1 , wherein the tumor is melanoma.

Assignees

• Merck Sharp & Dohme

Inventors

• Ayers Mark
• Lunceford Jared
• Loboda Andrey
• Nebozhyn Michael
• Mcclanahan Terrill K
• Hirsch Heather

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/566

  using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title

• G01N33/543

  with an insoluble carrier for immobilising immunochemicals · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title